125.21
0.13%
-0.16
After Hours:
125.21
Merck & Co Inc stock is currently priced at $125.21, with a 24-hour trading volume of 4.78M.
It has seen a -0.13% decreased in the last 24 hours and a +3.10% rose in the past month.
The chart indicates a potential bearish trend, as the stock is below the $125.4 pivot point. If it approaches the $124.7 support level, significant changes may occur.
Merck & Co Inc Stock (MRK) Financials Data
Merck & Co Inc (MRK) Revenue 2024
MRK reported a revenue (TTM) of $60.11 billion for the quarter ending December 31, 2023, a +1.40% rise year-over-year.
Merck & Co Inc (MRK) Net Income 2024
MRK net income (TTM) was $365.00 million for the quarter ending December 31, 2023, a -97.49% decrease year-over-year.
Merck & Co Inc (MRK) Cash Flow 2024
MRK recorded a free cash flow (TTM) of $9.14 billion for the quarter ending December 31, 2023, a -37.83% decrease year-over-year.
Merck & Co Inc (MRK) Earnings per Share 2024
MRK earnings per share (TTM) was $0.14 for the quarter ending December 31, 2023, a -97.55% decline year-over-year.
Merck & Co Inc Stock (MRK) Insider Trading
Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
---|---|---|---|---|---|---|---|
Merck & Co., Inc. | 10% Owner |
Mar 11 '24 |
Buy |
23.00 |
21,397,205 |
492,135,715 |
1,000 |
Davis Robert M | Chairman, CEO & President |
Feb 14 '24 |
Option Exercise |
73.73 |
85,021 |
6,268,598 |
433,348 |
Litchfield Caroline | EVP & CFO |
Feb 14 '24 |
Option Exercise |
58.08 |
38,291 |
2,223,941 |
89,199 |
Davis Robert M | Chairman, CEO & President |
Feb 14 '24 |
Sale |
125.40 |
85,021 |
10,661,574 |
348,327 |
Litchfield Caroline | EVP & CFO |
Feb 14 '24 |
Sale |
125.50 |
38,291 |
4,805,520 |
50,908 |
Davis Robert M | Chairman, CEO & President |
Feb 13 '24 |
Option Exercise |
74.18 |
150,000 |
11,127,160 |
498,327 |
Davis Robert M | Chairman, CEO & President |
Feb 13 '24 |
Sale |
125.85 |
150,000 |
18,877,424 |
348,327 |
Romanelli Joseph | President, Human Health Int?l |
Feb 13 '24 |
Sale |
124.89 |
1,000 |
124,888 |
19,569 |
Li Dean Y | Executive VP & President, MRL |
Feb 09 '24 |
Option Exercise |
62.07 |
14,702 |
912,553 |
60,944 |
Li Dean Y | Executive VP & President, MRL |
Feb 09 '24 |
Sale |
125.50 |
14,702 |
1,845,083 |
46,242 |
Merck & Co Inc Stock (MRK) Latest News
Unveiling 17 Analyst Insights On Merck & Co
Benzinga
Merck (MRK) Reports Next Week: Wall Street Expects Earnings Growth
Zacks Investment Research
Merck (MRK) Advances While Market Declines: Some Information for Investors
Zacks Investment Research
Top Analyst Reports for Microsoft, Novo Nordisk & United Parcel
Zacks Investment Research
Better Growth Play: Merck or The Vanguard Growth Index Fund?
The Motley Fool
Merck Paid $208 Million to Stop Its Drugs From Working. Here's Why That's Bullish.
The Motley Fool
About Merck & Co Inc
Merck & Co., Inc. provides healthcare solutions worldwide. It operates in four segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The company offers therapeutic and preventive agents to treat cardiovascular diseases, type 2 diabetes, asthma, nasal allergy symptoms, allergic rhinitis, chronic hepatitis C virus, HIV-1 infection, fungal, intra-abdominal infections, hypertension, arthritis and pain, inflammatory, osteoporosis, and fertility diseases. It also provides neuromuscular blocking agents; anti-bacterial products; cholesterol modifying medicines; and vaginal contraceptive products. In addition, the company offers products to prevent chemotherapy-induced and post-operative nausea and vomiting; treat brain tumors, and metastatic non-small-cell lung cancer; prevent diseases caused by human papillomavirus; and vaccines for measles, mumps, rubella, varicella, shingles, rotavirus gastroenteritis, and pneumococcal diseases. Further, it offers antibiotic and anti-inflammatory drugs to treat infectious and respiratory diseases, fertility disorders, and pneumonia in cattle, horses, and swine; vaccines for poultry; parasiticide for sea lice in salmon; and antibiotics and vaccines for fishes. The company also provides companion animal products, such as ointments; diabetes mellitus; anthelmintic products; fluralaner products to treat fleas and ticks in dogs; and products for protection against bites from fleas, ticks, mosquitoes, and sandflies. Merck & Co., Inc. has collaborations with Pfizer Inc., AstraZeneca PLC, Bayer AG, Eisai Co., Ltd., IO Biotech, Premier Inc., Cue Biopharma, Inc., Foundation Medicine, Inc., Daiichi Sankyo Company, Limited, and Cold Genesys, Inc. It serves drug wholesalers and retailers, hospitals, government agencies and entities, physicians, physician distributors, veterinarians, distributors, animal producers, and managed health care providers. The company was founded in 1891 and is headquartered in Kenilworth, New Jersey.
Cap:
|
Volume (24h):